<DOC>
	<DOC>NCT00801450</DOC>
	<brief_summary>Triamcinolone has already been used by different routes of administration to treat diabetic macular edema. In the present study, intravitreal injection (IVI) and posterior sub-Tenon's infusion (STI) of triamcinolone acetonide (TA) during phacoemulsification cataract surgery in eyes with refractory diffuse diabetic macular edema are tested.</brief_summary>
	<brief_title>Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Refractory diffuse DME unresponsive to focal laser photocoagulation Best corrected visual acuity between 20/800 and 20/40; Central subfield macular thickness greater than 300 Âµm Previous ocular surgery Glycosylated hemoglobin (Hb A1C) rate above 10% History of glaucoma or ocular hypertension Loss of vision as a result of other causes Systemic corticoid therapy Severe systemic disease Any condition affecting followup or documentation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>diabetes</keyword>
	<keyword>macular edema</keyword>
	<keyword>triamcinolone</keyword>
	<keyword>cataract</keyword>
	<keyword>refractory diabetic macular edema</keyword>
</DOC>